BI
RNTX

BVF Inc’s Rein Therapeutics RNTX Stock Holding History

BVF Inc’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-236,835
Closed -$561K – 80
2022
Q4 		$561K Sell
236,835
-26,443
-10% -$88.8K 0.02% 75
2022
Q3 		$1.09M Hold
263,278
– – 0.04% 74
2022
Q2 		$1.37M Hold
263,278
– – 0.07% 71
2022
Q1 		$2.7M Hold
263,278
– – 0.11% 70
2021
Q4 		$2.96M Hold
263,278
– – 0.11% 75
2021
Q3 		$5.37M Hold
263,278
– – 0.21% 64
2021
Q2 		$6.58M Hold
263,278
– – 0.25% 56
2021
Q1 		$7.53M Buy
+263,278
New +$9.02M 0.28% 55

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return

BVF Inc's RNTX Position: Q1 2023 in Review

BVF Inc sold out of Rein Therapeutics (RNTX) in Q1 2023, closing a stake of 236,835 shares — an estimated $561K sold.

BVF Inc first reported a position in RNTX in Q1 2021 and held it in 8 quarters. The position peaked at $7.53M in Q1 2021. 19 funds tracked by Wall St. Rank hold RNTX as of Q1 2023.

  • BVF Inc reported no remaining Rein Therapeutics position as of Q1 2023 after selling out during the quarter.
  • BVF Inc sold 236,835 Rein Therapeutics shares in Q1 2023, an estimated $561K.
  • BVF Inc first reported a position in Rein Therapeutics in Q1 2021 and held it in 8 quarters.
  • BVF Inc's Rein Therapeutics position peaked at $7.53M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2023.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.